SPCC338.18 Antibody

What is SPCC338.18 Antibody and what does it target?

SPCC338.18 Antibody targets the protein product of the SPCC338.18 gene in Schizosaccharomyces pombe. The nomenclature follows standard S. pombe gene designation conventions where "SP" indicates S. pombe, "C" designates chromosome III, and "C338.18" identifies the specific open reading frame. This antibody enables detection of the corresponding protein in various experimental systems and cellular contexts. While specific epitope information is limited in available literature, researchers should note that antibody validation is essential to confirm specificity in their particular experimental systems. The antibody is likely polyclonal based on similar research-grade antibodies, though specific information about the immunogen used for its generation requires manufacturer documentation review.

What common research techniques can SPCC338.18 Antibody be used for?

Based on standard applications of antibodies in yeast research, SPCC338.18 Antibody would likely be suitable for multiple detection methods:

*Optimal dilutions should be determined empirically for each application

Similar antibodies targeting S. pombe proteins have been successfully employed using these techniques, particularly in Western blot analysis and immunofluorescence applications as demonstrated in comparable research methodologies .

How should researchers validate SPCC338.18 Antibody specificity?

Antibody validation is a critical step before proceeding with experiments to ensure reliable and reproducible results. For SPCC338.18 Antibody, researchers should implement a multi-step validation strategy:

• Genetic validation: Compare antibody signal between wild-type S. pombe and strains with SPCC338.18 gene deleted or downregulated. The absence or significant reduction of signal in knockout/knockdown strains strongly supports antibody specificity.

• Tagged protein approach: Generate a strain expressing the SPCC338.18 protein with an epitope tag (e.g., HA or GFP) and compare the localization patterns detected by both anti-tag antibody and SPCC338.18 Antibody. Co-localization confirms target specificity.

• Western blot analysis: Verify a single band of appropriate molecular weight (or multiple bands representing known isoforms) in wild-type samples that disappears in knockout controls.

• Absorption controls: Pre-incubate the antibody with purified target protein or the immunizing peptide before staining to block specific binding sites. Significant signal reduction indicates specificity for the target epitope.

Researchers should document these validation steps thoroughly, as they provide critical evidence for antibody reliability. Similar validation approaches have been employed for antibodies used in S. pombe research contexts .

How do fixation methods affect SPCC338.18 Antibody performance in immunofluorescence microscopy?

For immunofluorescence applications with SPCC338.18 Antibody, methanol fixation has proven effective for other S. pombe protein detection . A recommended protocol includes:

• Harvesting yeast cells at mid-log phase (OD600 = 0.5-0.8)

• Fixing in cold methanol (-20°C) for 8 minutes

• Washing three times in phosphate-buffered saline (PBS)

• Blocking with 5% BSA in PBS for 30 minutes

• Proceeding with primary antibody incubation (typically overnight at 4°C)

Researchers should empirically determine optimal fixation conditions by comparing different methods. The relationship between fixation protocol and epitope accessibility is particularly critical when attempting co-localization studies with other cellular markers.

What methodological considerations are essential when comparing results from different antibody detection systems?

When comparing results from different antibody detection systems, such as between SPCC338.18 Antibody and other antibodies targeting related proteins, researchers must consider several methodological factors:

• Antibody sensitivity differences: As demonstrated in comparative studies of PD-L1 antibodies, different clones (like 22C3 vs SP142) can show significantly different detection sensitivities despite targeting the same protein . The median percentage of positively stained cells can vary dramatically depending on the antibody clone used .

• Standardization of scoring/quantification: Establish consistent thresholds for positive staining. In IHC studies comparing antibody clones, different positivity cut-offs (≥1%, ≥5%, ≥50% of cells) significantly impact interpretation .

• Cell-type specific differences: Consider that some antibodies may show different staining patterns in different cell types. For example, PD-L1 antibodies showed significantly higher staining percentages in squamous cell carcinoma compared to non-squamous cell samples .

• Protocol harmonization: Standardize sample preparation, antigen retrieval, antibody dilution, incubation times, and detection systems to enable valid comparisons.

• Statistical analysis: When comparing antibody performance, use appropriate statistical methods to determine if observed differences are significant, as demonstrated in comparative antibody studies .

These considerations are essential for accurately interpreting differences observed between antibody detection systems and avoiding methodology-related artifacts.

How can SPCC338.18 Antibody be used in studies investigating protein complex formation?

Investigating protein complexes involving SPCC338.18 requires specialized methodological approaches:

• Co-immunoprecipitation optimization:

  • Use mild lysis conditions to preserve protein-protein interactions (e.g., buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate)

  • Pre-clear lysates with protein A/G beads before immunoprecipitation

  • Incubate with SPCC338.18 Antibody (3-5 μg) overnight at 4°C

  • Capture antibody-protein complexes with protein A/G beads

  • Wash extensively with decreasing detergent concentrations

  • Elute and analyze by Western blot for interacting partners

• Proximity ligation assay (PLA):

  • Fix cells using optimized protocols as determined in section 2.1

  • Incubate with SPCC338.18 Antibody and antibody against potential interacting partner

  • Apply PLA probes and perform ligation and amplification

  • Quantify PLA signal using appropriate imaging software

• Mass spectrometry identification of complexes:

  • Perform immunoprecipitation with SPCC338.18 Antibody

  • Process samples for mass spectrometry analysis

  • Compare to control immunoprecipitations to identify specific interactors

  • Validate key interactions by reciprocal co-immunoprecipitation

• Controls and validation:

  • Include isotype control antibodies

  • Perform reverse immunoprecipitation with antibodies against suspected binding partners

  • Verify interactions using recombinant tagged proteins

These approaches enable comprehensive investigation of protein complexes while minimizing artifacts and false positives.

What is the optimal protocol for Western blot using SPCC338.18 Antibody?

Based on standard protocols for antibodies used in S. pombe research , the following Western blot protocol would be suitable for SPCC338.18 Antibody:

Sample preparation:

• Harvest 10-20 ml of yeast culture (OD600 = 0.5-1.0)

• Pellet cells by centrifugation (3,000 × g, 5 minutes)

• Resuspend in 200 μl lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 10% glycerol, 1 mM PMSF, protease inhibitor cocktail)

• Add glass beads and disrupt cells (6 cycles of 30 seconds vortexing, 30 seconds on ice)

• Centrifuge at 13,000 × g for 15 minutes at 4°C

• Transfer supernatant to a new tube and determine protein concentration

SDS-PAGE and transfer:

• Load 20-40 μg protein per lane

• Separate proteins on 10-12% SDS-PAGE gel

• Transfer to PVDF membrane (100V for 1 hour or 30V overnight at 4°C)

Immunoblotting:

• Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with SPCC338.18 Antibody (recommended starting dilution 1:1000) in blocking buffer overnight at 4°C

• Wash 3× with TBST, 10 minutes each

• Incubate with HRP-conjugated secondary antibody (1:5000) for 1 hour at room temperature

• Wash 3× with TBST, 10 minutes each

• Develop using ECL substrate and detect signal

Expected results:

• The apparent molecular weight of SPCC338.18 protein should be verified against predicted size

• Include positive control (wild-type S. pombe extract) and negative control (SPCC338.18 deletion strain if available)

This protocol incorporates methodological considerations derived from standard approaches used in S. pombe protein detection .

How can researchers troubleshoot non-specific binding issues with SPCC338.18 Antibody?

When encountering non-specific binding with SPCC338.18 Antibody, researchers should implement a systematic troubleshooting approach:

For Western blot applications:

• Test alternative blocking agents (BSA, casein, commercial blockers)

• Increase wash stringency with higher detergent concentration (up to 0.1% SDS in TBST)

• Optimize primary antibody incubation temperature and time

• Consider using specialized S. pombe-optimized extraction buffers containing appropriate detergents

For immunofluorescence applications:

• Test different fixation and permeabilization methods

• Include 0.1% BSA in all antibody dilution buffers

• Extend washing steps (5 washes of 5 minutes each)

• Preabsorb antibody with fixed, permeabilized cells from negative control strains

These approaches systematically address common sources of non-specific binding and have been successfully applied to antibody optimization in yeast research contexts .

How should researchers design experiments to distinguish between true positive signals and artifacts when using SPCC338.18 Antibody?

Designing experiments that differentiate between true signals and artifacts requires rigorous controls and validation steps:

• Genetic controls:

  • Include SPCC338.18 deletion strain alongside wild-type samples

  • Use strains with SPCC338.18 gene under regulated promoter to demonstrate signal correlation with expression level

  • For tagged versions, compare signal from antibody with anti-tag antibody signal

• Technical controls:

  • Secondary antibody-only samples to identify non-specific secondary binding

  • Isotype control antibody to identify Fc receptor or non-specific primary binding

  • Pre-immune serum control (if available) to establish baseline staining

• Signal validation approaches:

  • Peptide competition assay: Pre-incubate antibody with immunizing peptide

  • Orthogonal detection: Verify findings using alternative detection methods

  • Biological validation: Confirm expected changes in signal under conditions known to affect target protein (e.g., cell cycle regulation, stress response)

• Quantification and statistical analysis:

  • Establish objective quantification methods with defined thresholds

  • Perform multiple biological replicates (minimum n=3)

  • Apply appropriate statistical tests to determine significance

  • Consider blinded analysis to eliminate observer bias

• Specialized experimental designs:

  • For protein-protein interactions: Use FRET or BRET approaches as orthogonal validation

  • For localization: Correlate with well-established compartment markers

  • For protein expression: Compare with RNA levels by RT-qPCR

By implementing these comprehensive experimental design principles, researchers can confidently distinguish authentic SPCC338.18 signals from experimental artifacts, ensuring reliable and reproducible research outcomes.